FB-607

FB-607 is an investigational, proprietary enteric-coated, pH-sensitive coformulation of the non-systemic rifamycin antibiotic rifaximin and the mucolytic/antioxidant agent N-acetylcysteine (NAC). It is designed to target the intestinal mucus layer and biofilms, utilizing NAC's mucolytic properties to cleave disulfide bonds in mucoproteins and reduce mucus viscosity. This action enhances rifaximin's penetration and access to bacteria within the intestinal mucus layer. Developed under an exclusive license from Cedars-Sinai, FB-607 is primarily being evaluated in a Phase 2 clinical trial for the treatment of irritable bowel syndrome with diarrhea (IBS-D), with potential for development in other indications such as hepatic encephalopathy.